1. Bexarotene: a promising anticancer agent

   • Liyan Qu
   • Xiuwen Tang

   Mini Review 24 September 2009 Pages: 201 - 205

2. Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α₅β₁ integrin monoclonal antibody (volociximab) in cancer patients

   • Chee M. Ng
   • S. Bai
   • A. W. Tolcher

   Original Article 26 May 2009 Pages: 207 - 217

   

3. Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer

   • Junichi Kurebayashi
   • Mamoru Nukatsuka
   • Mamoru Kiniwa

   Original Article 20 May 2009 Pages: 219 - 225

   

4. A phase I study of larotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naïve patients with stage IIIB or stage IV non-small cell lung cancer

   • Francisco Robert
   • Karen Harper
   • Sunil Gupta

   Original Article 29 May 2009 Pages: 227 - 234

5. Phase 1 first-in-human clinical study of S-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors

   • Apostolia Maria Tsimberidou
   • Michelle A. Rudek
   • Razelle Kurzrock

   Original Article 31 May 2009 Pages: 235 - 241

   

6. Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent d-19575 (glufosfamide) in patients with solid tumors

   • Toshio Shimizu
   • Isamu Okamoto
   • Kazuhiko Nakagawa

   Original Article 29 May 2009 Pages: 243 - 250

   

7. Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer

   • Ken-ichi Fujita
   • Yuichi Ando
   • Yasutsuna Sasaki

   Original Article 23 May 2009 Pages: 251 - 258

   

8. Promising overall survival of patients with recurrent/metastatic squamous cell carcinoma of head and neck receiving gemcitabine plus cisplatin treatment: report of a multi-center phase II study

   • Muh-Hwa Yang
   • Peter Mu-Hsin Chang
   • Po-Min Chen

   Original Article 24 May 2009 Pages: 259 - 265

   

9. Celecoxib prevents tumor growth in an animal model by a COX-2 independent mechanism

   • Amanda Leite Bastos-Pereira
   • Daiana Lugarini
   • Alexandra Acco

   Original Article 09 June 2009 Pages: 267 - 276

   

10. Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1α in tumor and normal cells

    • Gangjun Du
    • Haihong Lin
    • Lijuan Yu

    Original Article 26 May 2009 Pages: 277 - 287

    

11. Dual targeting of tumour cells and host endothelial cells by novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines

    • Seema-Maria Nathwani
    • Stephen Butler
    • Daniela M. Zisterer

    Original Article 29 May 2009 Pages: 289 - 300

    

12. Phase I/II study of the lipiodolization using DDP-H (CDDP powder; IA-call^®) in patients with unresectable hepatocellular carcinoma

    • Yo-ichi Yamashita
    • Akinobu Taketomi
    • Yoshihiko Maehara

    Original Article 03 June 2009 Pages: 301 - 307

    

13. Effect of antisense oligomer in controlling c-raf.1 overexpression during diethylnitrosamine-induced hepatocarcinogenesis in rat

    • Tanushree Das
    • Falguni Patra
    • Biswajit Mukherjee

    Original Article 05 June 2009 Pages: 309 - 318

    

14. Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials

    • Nse Ntukidem
    • Carlos Arce-Lara
    • Tanios Bekaii-Saab

    Original Article 09 June 2009 Pages: 319 - 324

    

15. Quantitative structure–property relationships of camptothecins in humans

    • Chao Xu
    • Thomas M. Barchet
    • Donald E. Mager

    Original Article 02 June 2009 Pages: 325 - 333

    

16. Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences

    • Amalia Azzariti
    • Letizia Porcelli
    • Angelo Paradiso

    Original Article 04 June 2009 Pages: 335 - 346

    

17. The effect of transcatheter arterial chemoembolization on phase II drug metabolism enzymes in patients with hepatocellular carcinoma

    • Yan Zhang
    • Yanyan Jia
    • Aidong Wen

    Original Article 11 June 2009 Pages: 347 - 352

    

18. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation

    • Brian Thiessen
    • Clinton Stewart
    • Elizabeth Eisenhauer

    Original Article 05 June 2009 Pages: 353 - 361

    

19. A water soluble prodrug of a novel camptothecin analog is efficacious against breast cancer resistance protein-expressing tumor xenografts

    • Mika Endo
    • Masanori Miwa
    • Hisafumi Yamada-Okabe

    Original Article 04 June 2009 Pages: 363 - 371

    

20. A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma

    • Hyun Young Woo
    • Si Hyun Bae
    • Korean Liver Cancer Study Group

    Clinical Trial Report 18 September 2009 Pages: 373 - 382

    

21. A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas

    • Shivaani Kummar
    • Martin E. Gutierrez
    • James H. Doroshow

    Clinical Trial Report 06 November 2009 Pages: 383 - 389

22. Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme

    • Giulio Metro
    • Alessandra Fabi
    • Carmine M. Carapella

    Clinical Trial Report 22 October 2009 Pages: 391 - 397

    

23. Bevacizumab induced reversible thrombocytopenia in a patient with recurrent high-grade glioma: a case report

    • Ticiana Leal
    • H. Ian Robins

    Short Communication 16 September 2009 Pages: 399 - 401

    

24. The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients

    • Aathavan Loganayagam
    • Monica Arenas-Hernandez
    • Anthony M. Marinaki

    Short Communication 01 October 2009 Pages: 403 - 406